CRSP - CRISPR Therapeutics AG

55.54
-2.150   -3.871%

Share volume: 2,245,429
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$57.69
-2.15
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 5%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.22%
1 Month
18.47%
3 Months
-8.67%
6 Months
-16.51%
1 Year
41.58%
2 Year
-0.22%
Key data
Stock price
$55.54
P/E Ratio 
0.00
DAY RANGE
$55.39 - $58.47
EPS 
-$6.47
52 WEEK RANGE
$33.03 - $78.48
52 WEEK CHANGE
$44.11
MARKET CAP 
4.998 B
YIELD 
N/A
SHARES OUTSTANDING 
95.985 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-04-2025
BETA 
1.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,850,615
AVERAGE 30 VOLUME 
$1,547,892
Company detail
CEO: Samarth Kulkarni
Region: US
Website: crisprtx.com
Employees: 460
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.

Recent news